sig

Full identifier: http://purl.org/np/RA3HAU7gjqWwHnuixmjacloazylNNDAEDxjsx1JmtUSec#sig

Searching for classes... Loading...

Searching for instances... Loading...

Searching for templates... Loading...

Minted in Nanopublication

 RA3HAU7gjq comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA3HAU7gjq...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) ""Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4.1) Women who are pregnant or may become pregnant (4.3) Nursing mothers (4.4). Hypersensitivity to any component of this medication (4.2) Active liver disease which may include unexplained persistent elevations of hepatic transaminase levels Hypersensitivity to any component of this medication Women who are pregnant or may become pregnant. Atorvastatin calcium may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of atorvastatin calcium use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. ATORVASTATIN CALCIUM SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, atorvastatin calcium should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1 ) It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require atorvastatin calcium treatment should not breastfeed their infants [see Use in Specific Populations (8.3)"" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA3HAU7gjq... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-08-23T12:06:13.772+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA3HAU7gjq... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .
This is the identifier for this whole nanopublication. http://purl.org/np/RA3HAU7gjq... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA3HAU7gjq... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Loading...

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)